Trastuzumab for HER2 Positive Breast Cancer: 78 Real Stories

Stage IV HER2-Positive Breast Cancer: Leftfootforward's Survivor Story

Patient Info: Leftfootforward, Female, Under 40 | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Brain | Liver

Leftfootforward was diagnosed with Stage IIB HER2-positive breast cancer in 2010 and metastatic brain/liver disease in 2012; after systemic therapy, Gamma Knife, craniotomy for necrotic tissue, partial liver lobectomy, and resumed Herceptin, her latest scans showed no evidence of disease.

BreastCancer.org (ES)Read more →

Stage II HER2-Positive Breast Cancer: Frédérique's Survivor Story

Patient Info: Frédérique, Female, 40s | Stage II

Biomarkers: HER2-positive

Frédérique was listed as having complete remission after Herceptin/trastuzumab treatment for HER2-positive Stage II breast cancer.

Fondation ARCRead more →

Stage IV HER2-Positive Breast Cancer: Pilar's Patient Story

Patient Info: Pilar, Female, 40s | Stage IV

Biomarkers: Hormone receptor-positive; HER2-positive

Pilar was living with metastatic hormone receptor-positive, HER2-positive breast cancer, continuing systemic treatment with Zoladex, aromatase inhibitors, trastuzumab, and pertuzumab, and managing side effects with rehabilitation support.

HER2-Positive Breast Cancer: Jim's Patient Story

Patient Info: Jim Keegan, Male, 70+

Biomarkers: HER2-positive; BRCA1/BRCA2 negative

Jim completed surgery, chemotherapy and 1 year of Herceptin for early-stage HER2-positive male breast cancer, then continued tamoxifen and yearly MSK surveillance while advocating for male breast cancer awareness.

Memorial Sloan KetteringRead more →

HER2-Positive Breast Cancer Treatment Followed by Multiple Myeloma

Patient Info: Anonymized, female, 50s | Stage II

Biomarkers: ER-negative; PR-negative; HER2 3+; Ki-67 70%

Postoperative imaging showed no breast cancer recurrence or distant metastasis, and the breast cancer was described as stable when a separate multiple myeloma diagnosis was made.

PubMed CentralRead more →

Stage IV HR-Positive Breast Cancer: Alison's Survivor Story

Patient Info: Alison, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Cervical/neck lymph nodes

Alison reported complete remission since August 2017 while continuing intermittent maintenance chemotherapy, most recently 1 month of treatment followed by 2 months off.

The Patient StoryRead more →

Stage III HR-Positive Invasive Ductal Carcinoma: Stefanie's Survivor Story

Patient Info: Stefanie, Female | Stage III

Biomarkers: ER-positive, PR-positive and HER2-positive

Stefanie completed chemotherapy, breast-conserving surgery, prolonged Herceptin and 30 radiation treatments, then moved into survivorship while still adjusting to the lasting effects of treatment.

The Patient StoryRead more →

Stage IV HR-Positive Invasive Ductal Carcinoma: Shari's Patient Story

Patient Info: Shari S., Female | Stage IV

Biomarkers: ER-positive, PR-positive and HER2-positive; no inherited cancer mutation was identified

Metastatic Site: Brain; other initial metastatic sites were not named

Systemic imaging after chemotherapy showed no active disease, but brain metastases later required stereotactic radiation. Shari remained stage 4, continued Herceptin every 3 weeks and underwent brain MRI every 3–4 months.

The Patient StoryRead more →

Stage III HER2-Positive Breast Cancer: Genoa's Survivor Story

Patient Info: Genoa M., Female | Stage III

Biomarkers: HER2-positive; ER-positive

As of June 2026, Genoa had completed treatment for Stage III HER2-positive, ER-positive breast cancer with neoadjuvant Taxotere/carboplatin/trastuzumab, lumpectomy, and radiation, and was focused on survivorship and rebuilding life after treatment.

The Patient StoryRead more →

Stage IV HER2-Positive Invasive Ductal Carcinoma: Renee's Patient Story

Patient Info: Renee N., Female | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Brain

As of June 2026, Renee’s public story described living with metastatic HER2-positive breast cancer as a chronic illness, after brain radiation and while on Kadcyla every 3 weeks with stable scans reported in December 2019 and early March 2020.

The Patient StoryRead more →

Stage II HR-Positive Breast Cancer: Rach's Patient Story

Patient Info: Rach D., Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of June 2026, Rach described Stage II triple-positive breast cancer treated with fertility preservation, 6 rounds of neoadjuvant TCHP including Herceptin, Zoladex ovarian suppression, and double mastectomy with reconstruction.

The Patient StoryRead more →

Glycogen-rich clear cell breast carcinoma: HER2-positive early-stage case with disease-free follow-up

Patient Info: Anonymized, Female, 60s | Stage I

Biomarkers: ER-positive; HER2-positive; PR-negative; Ki-67 ~10%; intracytoplasmic glycogen confirmed

At 1-year follow-up, she had no evidence of breast cancer recurrence.

PubMed CentralRead more →

HER2-positive breast cancer: brain recurrence, T-DXd liver injury, and later progression

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2-positive; hormone receptor-negative; grade 3 infiltrative breast carcinoma

Metastatic Site: brain; thoracic lymph nodes

As of October 2025, the patient had developed brain and thoracic nodal recurrence after HER2-directed treatment, experienced T-DXd-associated liver injury, progressed after later paclitaxel/trastuzumab, and died at home in December 2024 under palliative care.

PubMed CentralRead more →

Stage IV HER2-Positive Breast Cancer: Paul's Patient Story

Patient Info: Paul Forgette, Male, 60s | Stage IV

Biomarkers: HER2-positive; triple-positive breast cancer; CHEK2 mutation

Metastatic Site: Bones; lymph nodes

By October 2025, 9 months after starting Enhertu, Paul’s Stage IV HER2-positive male breast cancer was described as dormant, not cured, with continued City of Hope care and integrative support.

City of HopeRead more →

HER2-positive Stage IV breast cancer: T-DM1 extravasation wound healed after multidisciplinary care

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER 90% positive; PR 70% positive; HER2 IHC 3+

Metastatic Site: pelvis

As of October 2025, the T-DM1 extravasation wound had almost fully healed within about 4 weeks, and the patient continued adjuvant T-DM1 through a port; longer cancer-control status was not described.

PubMed CentralRead more →

HER2-positive luminal B breast cancer with axillary tumor deposits: no recurrence after multimodal therapy

Patient Info: Anonymized, Female, 50s

Biomarkers: HER2-positive

After neoadjuvant therapy, mastectomy, axillary dissection, continued hormone therapy, and trastuzumab, she remained in good clinical condition with no detected recurrence.

PubMed CentralRead more →

HER2-positive invasive lobular breast cancer in a transgender man: disease-free after multimodality care

Patient Info: Anonymized, transgender man, 70+ | Stage III

Biomarkers: HER2-positive invasive lobular breast cancer, ER/PR negative

Nearly 2 years after diagnosis, he remained disease-free while continuing survivorship care and counseling after discontinuing testosterone therapy.

PubMed CentralRead more →

Stage IIB HER2-positive apocrine breast carcinoma treated with chemotherapy, trastuzumab, radiation, and tamoxifen

Patient Info: Anonymized, Female, Under 40 | Stage II

Biomarkers: ER 80%; PR 5%; HER2-positive by HercepTest and FISH; Ki-67 15%; AR testing not performed

At 7 months of follow-up, the patient remained in remission, with no locoregional recurrence or distant metastasis reported.

PubMed CentralRead more →

HER2-positive node-positive breast cancer: mastectomy and adjuvant TCbHP

Patient Info: Anonymized, Female, Under 40 | Stage III

Biomarkers: HER2-positive breast cancer with ER/PR positivity, PD-L1 CPS 25

Adjuvant TCbHP was initiated after surgery, the first cycle was tolerated with supportive care, and regular monitoring was ongoing without evidence of distant recurrence or metastasis reported.

PubMed CentralRead more →

HER2-positive breast cancer with brain, skin, and lymph-node metastases responding to dual-targeted therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: HER2-positive breast cancer. Initial tumor was ER/PR negative with Ki-67 30%; skin metastasis had Ki-67 70%.

Metastatic Site: brain, left cervical lymph nodes, skin of left chest…

After 1 cycle of inetetamab trastuzumab, pyrotinib, and capecitabine, skin metastases regressed, CEA and CA125 decreased, brain lesions shrank, and the largest lesion decreased by about 46%, meeting partial response; disease remained stable as of September 2024.

PubMed CentralRead more →

HER2-Positive Pleomorphic Lobular Breast Cancer in a 43-Year-Old Woman

Patient Info: Anonymized, Female, 40s

Biomarkers: HER2-positive, ER-negative, PR-negative

Postoperative adjuvant treatment continued with HER2-targeted therapy after chemotherapy and radiation.

PubMed CentralRead more →

Stage IV HER2-Positive Breast Cancer: Kathleen's Patient Story

Patient Info: Kathleen McEvoy-Schufreider, female, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver, bones

Kathleen continued long-term treatment for metastatic breast cancer, including infusions every 3 weeks after resuming the PATINA regimen outside the trial.

Dana-FarberRead more →

HER2-Positive Breast Cancer With Brain and Leptomeningeal Metastases Responding to Intrathecal Treatment

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: brain, leptomeninges

More than 5 years after her September 2019 diagnosis, neurological symptoms had resolved, cerebrospinal fluid remained negative for tumor cells, and maintenance treatment was continuing in February 2025.

PubMed CentralRead more →

HER2-positive breast cancer with brain metastases: responding well to T-DXd

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive / HER2 IHC 3+

Metastatic Site: brain (left cerebellum, left frontal lobe, medulla)

After 14 months and 19 doses of T-DXd, brain metastases remained controlled with no symptomatic or radiological relapse and no severe T-DXd-related adverse events.

PubMed CentralRead more →